AZ stays on track for $80B revenue goal as cancer meds, rare disease sales help offset Ultomiris miss

AstraZeneca remains on track to achieve its $80 billion annual revenue target by 2030, despite recent trial setbacks involving its rare disease drug Ultomiris.

Strong sales of cancer medicines and rare disease therapies, especially in oncology and respiratory and immunology, are driving revenue growth and offsetting the Ultomiris miss.

Key oncology drugs such as Tagrisso, Imfinzi, Enhertu, and Calquence, along with rare disease products like Ultomiris and Strensiq, continue to deliver robust growth, supporting the long-term ambition.

AstraZeneca reiterated its guidance for mid-to-high single-digit revenue growth in 2026 and highlighted over 20 high-value pipeline readouts expected in the next 18 months that could further boost revenue toward the $80 billion goal.